iifl-logo-icon 1

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Glenmark, Pfizer reach settlement agreement for Axitinib Tablets

22 Nov 2022 , 10:09 AM

glenmark pharma

Glenmark Pharmaceuticals Limited and Glenmark Pharmaceuticals Inc., USA (Glenmark) have reached a settlement agreement with Pfizer Inc., PF Prism IMB B.V., and PF Prism C.V., (Pfizer) for Axitinib Tablets, 1 mg and 5 mg, the generic version of Pfizer’s Inlyta Tablets, 1 mg and 5 mg.

Glenmark had previously announced that the United States Food and Drug Administration (USFDA) had tentatively approved their generic Axitinib Tablets, 1 mg, and 5 mg, for release on November 30, 2020.

According to IQVIATM sales data for the 12-month period ending September 2022, the Inlyta Tablets, 1 mg, and 5 mg market generated approximately $644.5 million in annual sales.

Glenmark’s current portfolio includes 177 products that are authorized for distribution in the United States, as well as 47 ANDAs that are awaiting FDA approval.

Glenmark expressed that it continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio, in addition to these internal filings.

At around 10.08 AM, Glenmark Pharmaceuticals was trading at Rs417 up by 1.32% from its previous closing of Rs411.55 on the BSE. The scrip opened at Rs412.05 and touched intraday high and low of Rs417.70 and Rs412.05 respectively.

For feedback and suggestions, write to us at editorial@iifl.com

Related Tags

  • Glenmark Pharma Drug
  • Glenmark Settlement News
  • Glenmark Stock News
  • Glenmark Updates
  • Glenmark USFDA Approval
  • Pfizer News
  • Pharma news
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.